Rachael Wingo Email

Chief Financial Officer . Invirsa

Current Roles

Employees:
13
Revenue:
$2.6M
About
Invirsa is developing a small molecule (INV-102) that promotes both DNA repair and the innate immune response to infection and injury. These actions lead to enhanced wound healing associated with reductions in inflammation and viral replication. INV-102 has demonstrated unprecedented efficacy in animal models of ocular sulfur mustard gas injury. Sulfur mustard is a dangerous chemical weapon, and INV-102 is the first drug to show promise in preventing its long-term effects. There is no current FDA approved therapy for this injury. In September of 2020, Invirsa received a $29.6M BARDA award ($14.4M plus $15.2M in milestones) to support the clinical development of INV-102 for the treatment of ocular sulfur mustard gas injury and other ocular injuries associated with DNA damage. The award covers development through Phase 3 clinical trials. Invirsa's initial commercial focus for INV-102 will be infectious keratoconjunctivitis as there is no treatment for the viral form of this disease which comprises 80% of all cases. INV-102 has demonstrated clear efficacy in animal models of infectious conjunctivitis.
Invirsa Address
1275 Kinnear Rd
null, null
Invirsa Email

Past Companies

Invirsa, IncChief Financial Officer
EmplifiVice President Finance
VelosioFinance Director

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.